Pillar Biosciences Raises $29.7M in Series C Financing
Summary
The company intends to use the funds to accelerate the expansion of in vitro diagnostic and research use only panels and advance its global commercial outreach. Gang Song, founder and CEO, Pillar Biosciences is a clinical cancer diagnostics company whose SLIMamp®- and PiVAT®-based products help high-throughput reference laboratories and clinical oncology laboratories boost their diagnostic productivity. Recently, a Pillar custom product received approval from New York State Department of Health. The company was also granted CE approval for its first in vitro diagnostic panel, the Pillar® ONCO/Reveal® Lung and Colon Cancer Assay, which guides the prescription of six different therapies simultaneously, reduces the need for repeat testing, and allows for treatment decisions in 4 days. Pillar also recently secured distributors in Israel, Hong Kong, Macau, South Korea, and ASEAN countries.